Efficacy of adding bevacizumab in the first-line chemotherapy of metastatic colorectal cancer: evidence from seven randomized clinical trials.

Gastroenterol Res Pract · 2014 · PMC4058184 · PMID 24971091

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not reach statistical significanceP = 0.08so close (0.05 < p ≤ 0.1)

In first-line bevacizumab-added chemotherapy, compared to chemotherapy alone, the meta-analysis of data did not reach statistical significance for OS (HR = 0.89; 95% CI = 0.78–1.02; P = 0.08) ( Figure 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.